We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+1.53%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$4.93B
AUM Growth
-$733M
Cap. Flow
-$52.9M
Cap. Flow %
-1.07%
Top 10 Hldgs %
45.48%
Holding
165
New
19
Increased
18
Reduced
16
Closed
21

Top Buys

Rank Stock Value
1
OTLY
Oatly Group
OTLY
+$37.3M
2
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$32.5M
3
TRML
Tourmaline Bio
TRML
+$31.6M
4
SAGE
Sage Therapeutics
SAGE
+$24.7M
5
VERV
Verve Therapeutics
VERV
+$20.8M

Top Sells

Rank Stock Value
1
BNTX icon
BioNTech
BNTX
+$98.3M
2
INTC icon
Intel
INTC
+$47M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$38.4M
4
AVGO icon
Broadcom
AVGO
+$34.8M
5
BEKE icon
KE Holdings
BEKE
+$34.2M

Sector Composition

Rank Sector Weight
1 Healthcare 75.69%
2 Consumer Discretionary 10.87%
3 Miscellaneous 10.83%
4 Consumer Staples 0.74%
5 Industrials 0.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMA
51
ImageneBio Inc
IMA
$57.7M
$21.8M 0.44%
129,126
– –
LENZ
52
LENZ Therapeutics
LENZ
$142M
$21.5M 0.44%
+100,000
New +$17.4M
ALBO
53
DELISTED
Albireo Pharma Inc
ALBO
$21.1M 0.43%
600,000
– –
NG icon
54
NovaGold Resources
NG
$3.17B
$20.8M 0.42%
2,600,000
– –
BDTX icon
55
Black Diamond Therapeutics
BDTX
$117M
$20.1M 0.41%
1,646,517
– –
NEXI
56
DELISTED
NexImmune, Inc. Common Stock
NEXI
$19.6M 0.4%
48,000
– –
GOSS icon
57
Gossamer Bio
GOSS
$65.4M
$19.2M 0.39%
29,487
– –
FHTX icon
58
Foghorn Therapeutics
FHTX
$262M
$18.4M 0.37%
1,720,720
– –
MRNS
59
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$17.9M 0.36%
1,000,000
+200,000
+25% +$3.22M
APTX
60
DELISTED
Aptinyx Inc. Common Stock
APTX
$17.3M 0.35%
6,116,493
– –
RPTX
61
DELISTED
Repare Therapeutics
RPTX
$17.1M 0.35%
550,000
– –
BBIO icon
62
BridgeBio Pharma
BBIO
$14.1B
$16.8M 0.34%
275,000
+25,000
+10% +$1.43M
RNAC icon
63
Cartesian Therapeutics
RNAC
$248M
$16.7M 0.34%
133,333
-16,667
-11% -$1.98M
AMAM
64
DELISTED
Ambrx Biopharma Inc
AMAM
$16.7M 0.34%
+850,000
New +$14.5M
MRSN
65
DELISTED
Mersana Therapeutics
MRSN
$16.3M 0.33%
48,000
– –
ZYME icon
66
Zymeworks
ZYME
$1.92B
$15.6M 0.32%
450,000
– –
IQ icon
67
iQIYI
IQ
$960M
$15.6M 0.32%
1,000,000
-25,000
-2% -$372K
DLO icon
68
dLocal
DLO
$4.37B
$15.5M 0.31%
+295,000
New +$11.3M
BLU
69
DELISTED
BELLUS Health Inc.
BLU
$14.8M 0.3%
4,750,000
– –
RLAY icon
70
Relay Therapeutics
RLAY
$4.14B
$14.6M 0.3%
400,000
– –
LFST icon
71
Lifestance Health
LFST
$5.11B
$13.9M 0.28%
+500,000
New +$13.2M
HARP
72
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$13.9M 0.28%
100,000
– –
NBTX
73
Nanobiotix
NBTX
$1.88B
$13.8M 0.28%
1,000,000
– –
TBIO
74
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$13.8M 0.28%
500,000
-500,000
-50% -$9.83M
EVLO
75
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
$13.7M 0.28%
50,000
– –
1 2
3
4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q2 2021 Portfolio in Review

As of Q2 2021, Artal Group held 165 positions worth $4.93B, down 13% from $5.66B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Artal Group's Q2 2021 filing shows 19 new, 18 increased, 16 reduced and 21 closed positions. Its largest new stake was Oatly Group: 75,000 shares worth $36.7M. The largest sale was BioNTech, an estimated $98.3M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, up from 70% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

  • Artal Group's largest Q2 2021 buy was Oatly Group: 75,000 shares worth $36.7M.
  • Artal Group added most to Sage Therapeutics in Q2 2021, an estimated $24.7M increase.
  • Artal Group's biggest Q2 2021 reduction was TG Therapeutics, cutting an estimated $27.5M.
  • Artal Group fully exited BioNTech in Q2 2021, selling an estimated $98.3M.
  • Artal Group's ten largest holdings make up 45% of its $4.93B portfolio in Q2 2021.
  • Artal Group opened 19 new positions and closed 21 in Q2 2021.
  • Artal Group's portfolio value fell 13% quarter-over-quarter to $4.93B.

Based on Artal Group's 13F filing for Q2 2021, filed 13 Aug 2021.